| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
89,067 |
78,015 |
$7.55M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
70,281 |
59,431 |
$6.69M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
34,618 |
28,035 |
$3.71M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
21,724 |
16,662 |
$3.03M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
12,672 |
7,285 |
$2.31M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
40,713 |
12,134 |
$1.87M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
21,424 |
19,688 |
$1.63M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
73,813 |
53,619 |
$1.54M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
8,347 |
6,991 |
$1.34M |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
3,478 |
249 |
$1.28M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
12,809 |
8,820 |
$1.18M |
| 82962 |
|
78,723 |
45,490 |
$1.17M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
24,680 |
19,521 |
$1.15M |
| 90999 |
Unlisted dialysis procedure, inpatient or outpatient |
2,654 |
207 |
$1.14M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
6,925 |
5,977 |
$1.07M |
| J9271 |
Injection, pembrolizumab, 1 mg |
744 |
479 |
$1.01M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
7,220 |
6,384 |
$984K |
| 81003 |
|
73,482 |
54,982 |
$871K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
90,108 |
58,707 |
$865K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
22,764 |
15,486 |
$848K |
| 84703 |
|
36,809 |
32,370 |
$824K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
13,397 |
12,254 |
$743K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
27,162 |
21,732 |
$728K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
2,084 |
202 |
$725K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
15,404 |
12,498 |
$638K |
| 70450 |
Computed tomography, head or brain; without contrast material |
9,267 |
7,688 |
$636K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
114,605 |
82,495 |
$620K |
| 80053 |
Comprehensive metabolic panel |
39,959 |
29,926 |
$610K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
9,095 |
8,273 |
$599K |
| 76818 |
|
10,670 |
5,449 |
$577K |
| A4657 |
Syringe, with or without needle, each |
1,965 |
188 |
$551K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
1,374 |
1,257 |
$540K |
| 96415 |
|
3,944 |
2,495 |
$516K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
4,908 |
4,642 |
$492K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
1,331 |
1,194 |
$484K |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
1,063 |
171 |
$483K |
| 86850 |
|
12,866 |
11,105 |
$461K |
| 20610 |
|
5,330 |
4,557 |
$443K |
| 97162 |
|
5,482 |
4,727 |
$430K |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
524 |
48 |
$386K |
| 76830 |
Ultrasound, transvaginal |
5,387 |
4,850 |
$372K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
1,814 |
1,283 |
$369K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
1,521 |
1,298 |
$357K |
| J2505 |
Injection, pegfilgrastim, 6 mg |
625 |
415 |
$352K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
9,101 |
6,824 |
$349K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
5,738 |
5,424 |
$338K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
1,703 |
1,464 |
$320K |
| 97161 |
|
5,120 |
4,408 |
$303K |
| 62323 |
|
1,111 |
1,004 |
$287K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
2,284 |
1,964 |
$284K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
50,282 |
36,243 |
$276K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,202 |
1,900 |
$274K |
| 87631 |
|
4,221 |
3,555 |
$269K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
4,378 |
4,117 |
$267K |
| 95885 |
|
2,799 |
2,380 |
$262K |
| 59025 |
Fetal non-stress test |
10,761 |
8,202 |
$261K |
| A9270 |
Non-covered item or service |
16,019 |
7,688 |
$257K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
11,110 |
9,899 |
$252K |
| 81001 |
|
41,275 |
34,783 |
$247K |
| 01999 |
|
10,729 |
9,321 |
$244K |
| 71046 |
Radiologic examination, chest; 2 views |
14,976 |
13,226 |
$238K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
6,691 |
5,702 |
$232K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
3,997 |
2,723 |
$225K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
710 |
650 |
$207K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
18,844 |
16,083 |
$205K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
2,336 |
2,131 |
$198K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
8,766 |
8,114 |
$197K |
| 73630 |
|
9,026 |
6,831 |
$194K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
4,585 |
4,074 |
$193K |
| 95811 |
|
560 |
504 |
$191K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
8,666 |
7,620 |
$183K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
1,016 |
875 |
$180K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
383 |
335 |
$170K |
| 36415 |
Collection of venous blood by venipuncture |
30,730 |
21,678 |
$160K |
| J7050 |
Infusion, normal saline solution, 250 cc |
4,413 |
1,660 |
$153K |
| J9299 |
Injection, nivolumab, 1 mg |
366 |
266 |
$151K |
| 73130 |
|
6,137 |
4,585 |
$150K |
| 96367 |
|
1,715 |
1,194 |
$147K |
| 71045 |
Radiologic examination, chest; single view |
25,165 |
20,084 |
$147K |
| 76536 |
|
2,269 |
2,036 |
$144K |
| J2323 |
Injection, natalizumab, 1 mg |
152 |
110 |
$143K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
3,331 |
2,864 |
$141K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
1,315 |
1,093 |
$140K |
| 72197 |
|
865 |
727 |
$138K |
| 84484 |
|
30,044 |
15,163 |
$138K |
| 76775 |
|
2,589 |
2,257 |
$138K |
| 84702 |
|
6,324 |
4,114 |
$133K |
| J1756 |
Injection, iron sucrose, 1 mg |
2,971 |
1,253 |
$133K |
| 73610 |
|
5,458 |
4,529 |
$130K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,693 |
1,529 |
$130K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
8,727 |
8,093 |
$128K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
12,923 |
10,865 |
$126K |
| 87077 |
|
7,813 |
6,788 |
$122K |
| 73030 |
|
5,450 |
4,332 |
$122K |
| J0897 |
Injection, denosumab, 1 mg |
1,033 |
818 |
$121K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
686 |
600 |
$116K |
| 82728 |
|
7,491 |
6,256 |
$114K |
| 95911 |
|
2,351 |
2,114 |
$113K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
1,521 |
1,257 |
$113K |
| 76642 |
|
3,255 |
2,710 |
$111K |
| 83735 |
|
27,265 |
18,032 |
$110K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
1,368 |
1,139 |
$110K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
4,500 |
4,129 |
$110K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
23,494 |
16,871 |
$109K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
4,499 |
3,983 |
$107K |
| 87340 |
|
7,490 |
6,522 |
$106K |
| 83550 |
|
5,414 |
4,403 |
$104K |
| 74183 |
|
711 |
609 |
$102K |
| 76770 |
|
1,720 |
1,545 |
$102K |
| J1644 |
Injection, heparin sodium, per 1000 units |
9,024 |
3,368 |
$101K |
| 36591 |
|
1,382 |
900 |
$101K |
| 96401 |
|
1,536 |
865 |
$101K |
| 84443 |
Thyroid stimulating hormone (TSH) |
18,527 |
15,456 |
$101K |
| 73560 |
|
4,109 |
2,685 |
$100K |
| 83970 |
|
1,755 |
1,519 |
$100K |
| 74174 |
|
497 |
433 |
$99K |
| 87081 |
|
4,337 |
4,022 |
$98K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
8,937 |
5,868 |
$95K |
| 86900 |
|
13,660 |
11,775 |
$94K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
6,862 |
6,388 |
$94K |
| 82247 |
|
1,127 |
916 |
$93K |
| 80076 |
|
21,661 |
17,756 |
$93K |
| 77062 |
|
1,192 |
1,137 |
$92K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
8,042 |
4,232 |
$91K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
5,277 |
1,988 |
$89K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
8,080 |
6,801 |
$88K |
| 95886 |
|
613 |
554 |
$88K |
| 80061 |
Lipid panel |
18,512 |
15,713 |
$88K |
| 94010 |
|
2,291 |
2,053 |
$87K |
| 78451 |
|
237 |
204 |
$87K |
| 85027 |
|
14,527 |
11,295 |
$87K |
| 72141 |
|
1,143 |
978 |
$86K |
| 88307 |
|
551 |
472 |
$85K |
| 71250 |
|
2,332 |
1,959 |
$85K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
15,298 |
10,775 |
$84K |
| 10060 |
|
1,174 |
1,051 |
$83K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
4,423 |
1,907 |
$81K |
| 73110 |
|
3,350 |
2,680 |
$81K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
21,448 |
18,342 |
$79K |
| G0378 |
Hospital observation service, per hour |
8,719 |
4,097 |
$79K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,942 |
2,590 |
$78K |
| 43235 |
|
398 |
354 |
$78K |
| 85610 |
|
13,642 |
10,202 |
$77K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
296 |
251 |
$75K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
4,203 |
3,669 |
$74K |
| 72100 |
|
3,153 |
2,803 |
$74K |
| 93308 |
|
1,482 |
1,254 |
$74K |
| 84100 |
|
17,519 |
11,734 |
$73K |
| 87210 |
|
5,955 |
5,223 |
$72K |
| 73562 |
|
3,578 |
2,478 |
$71K |
| 70496 |
|
652 |
555 |
$71K |
| 93970 |
|
2,146 |
1,861 |
$71K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
12,381 |
9,806 |
$66K |
| 96523 |
|
2,018 |
1,424 |
$66K |
| 58100 |
|
347 |
332 |
$64K |
| 70491 |
|
797 |
700 |
$61K |
| 96402 |
|
973 |
744 |
$60K |
| 36592 |
|
1,958 |
1,659 |
$59K |
| 86901 |
|
14,106 |
12,155 |
$59K |
| 93017 |
|
1,479 |
1,304 |
$58K |
| 64493 |
|
187 |
179 |
$58K |
| 73564 |
|
3,570 |
2,829 |
$58K |
| J3490 |
Unclassified drugs |
20,380 |
12,670 |
$57K |
| 81025 |
|
14,856 |
13,277 |
$57K |
| 73502 |
|
2,748 |
2,343 |
$57K |
| 93923 |
|
1,088 |
938 |
$56K |
| 93971 |
|
2,025 |
1,709 |
$55K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
10,389 |
3,546 |
$54K |
| 72110 |
|
1,319 |
1,216 |
$54K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
4,059 |
3,205 |
$54K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
499 |
294 |
$54K |
| 86780 |
|
7,576 |
6,519 |
$53K |
| 83690 |
|
14,223 |
11,776 |
$53K |
| 73221 |
|
627 |
485 |
$53K |
| 87486 |
|
3,804 |
3,552 |
$52K |
| 72040 |
|
1,471 |
1,297 |
$52K |
| 88184 |
|
2,624 |
2,094 |
$50K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
10,495 |
8,728 |
$50K |
| 86803 |
|
6,948 |
6,016 |
$50K |
| 97116 |
|
2,882 |
1,605 |
$50K |
| J2704 |
Injection, propofol, 10 mg |
13,992 |
11,111 |
$50K |
| 77080 |
|
1,666 |
1,475 |
$49K |
| 83605 |
|
8,686 |
6,529 |
$48K |
| 12011 |
|
504 |
471 |
$47K |
| 73590 |
|
2,628 |
2,147 |
$47K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
3,368 |
2,781 |
$46K |
| 86403 |
|
719 |
696 |
$46K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
80 |
57 |
$44K |
| 12001 |
|
570 |
523 |
$44K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
4,220 |
3,688 |
$43K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
11,392 |
9,454 |
$42K |
| 87070 |
|
1,422 |
1,177 |
$42K |
| 73080 |
|
1,949 |
1,641 |
$41K |
| 93798 |
|
828 |
115 |
$41K |
| 84439 |
|
4,906 |
4,033 |
$40K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
771 |
245 |
$40K |
| 74018 |
|
1,886 |
1,579 |
$39K |
| 70486 |
|
872 |
766 |
$39K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
1,304 |
1,132 |
$39K |
| 85730 |
|
7,128 |
5,877 |
$39K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
1,289 |
1,033 |
$38K |
| 97165 |
|
2,301 |
1,904 |
$38K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
4,506 |
3,844 |
$38K |
| 87205 |
|
5,161 |
4,381 |
$37K |
| 93296 |
|
2,917 |
2,468 |
$37K |
| J1815 |
Injection, insulin, per 5 units |
3,590 |
1,332 |
$37K |
| 82565 |
|
2,224 |
1,905 |
$37K |
| 96417 |
|
2,249 |
1,393 |
$36K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
8,393 |
7,352 |
$36K |
| 27096 |
|
94 |
93 |
$36K |
| 77065 |
Tomosynthesis, mammo |
1,588 |
1,379 |
$35K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
541 |
435 |
$34K |
| 36430 |
|
834 |
620 |
$34K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
14,719 |
11,769 |
$34K |
| 93458 |
|
85 |
67 |
$33K |
| 80069 |
|
2,135 |
1,605 |
$33K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
243 |
154 |
$31K |
| 73552 |
|
1,775 |
1,420 |
$31K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
817 |
619 |
$31K |
| 82550 |
|
4,231 |
3,088 |
$30K |
| 72170 |
|
1,894 |
1,565 |
$30K |
| 94726 |
|
1,062 |
958 |
$29K |
| 76882 |
|
575 |
490 |
$29K |
| 88142 |
|
2,672 |
2,399 |
$29K |
| 82607 |
|
4,958 |
4,122 |
$28K |
| 73090 |
|
1,591 |
1,332 |
$28K |
| 96377 |
|
190 |
117 |
$28K |
| 76825 |
|
242 |
227 |
$28K |
| 87536 |
|
2,342 |
1,921 |
$28K |
| 84112 |
|
224 |
197 |
$28K |
| 86762 |
|
4,623 |
4,073 |
$28K |
| 73522 |
|
1,282 |
1,138 |
$27K |
| 57454 |
|
147 |
136 |
$27K |
| 83020 |
|
4,019 |
3,581 |
$27K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
5,869 |
4,207 |
$27K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
903 |
705 |
$26K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
3,495 |
2,094 |
$26K |
| 82950 |
|
2,283 |
2,040 |
$26K |
| 94762 |
|
2,544 |
1,128 |
$25K |
| 20611 |
|
114 |
104 |
$25K |
| 87088 |
|
8,974 |
7,776 |
$25K |
| 71271 |
|
519 |
478 |
$25K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
7,763 |
5,219 |
$25K |
| 97166 |
|
1,108 |
869 |
$24K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
711 |
332 |
$24K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
799 |
547 |
$24K |
| 76801 |
|
2,223 |
1,801 |
$24K |
| 82553 |
|
2,186 |
1,211 |
$23K |
| 99153 |
Mod sedat endo service >5yrs |
1,909 |
1,623 |
$23K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
54 |
51 |
$23K |
| 93880 |
|
719 |
589 |
$22K |
| 73060 |
|
1,207 |
990 |
$22K |
| 83880 |
|
4,128 |
3,397 |
$22K |
| 99152 |
|
2,058 |
1,750 |
$22K |
| 96368 |
|
402 |
309 |
$22K |
| 20550 |
|
314 |
232 |
$21K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
466 |
440 |
$21K |
| 93975 |
|
555 |
483 |
$21K |
| 94060 |
|
294 |
259 |
$21K |
| 74178 |
|
308 |
246 |
$20K |
| 84481 |
|
1,839 |
1,405 |
$20K |
| 72131 |
|
778 |
655 |
$20K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
5,369 |
3,666 |
$20K |
| 86706 |
|
1,009 |
843 |
$20K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
7,354 |
5,919 |
$20K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
136 |
41 |
$20K |
| 77061 |
|
566 |
535 |
$19K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,036 |
943 |
$19K |
| 97535 |
Self-care/home management training, each 15 minutes |
2,764 |
1,514 |
$19K |
| J1453 |
Injection, fosaprepitant, 1 mg |
320 |
165 |
$19K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
6,140 |
3,820 |
$18K |
| 83615 |
|
4,540 |
3,527 |
$17K |
| 87186 |
|
4,668 |
3,972 |
$17K |
| 93325 |
|
1,048 |
936 |
$17K |
| 82043 |
|
4,783 |
4,055 |
$17K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
290 |
163 |
$17K |
| 95912 |
|
422 |
387 |
$17K |
| 58661 |
|
12 |
12 |
$17K |
| 88185 |
|
2,635 |
2,100 |
$17K |
| 77386 |
|
141 |
12 |
$17K |
| 54160 |
|
22 |
15 |
$16K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
3,975 |
1,971 |
$16K |
| 88342 |
|
1,772 |
1,445 |
$16K |
| 80074 |
|
1,766 |
1,486 |
$16K |
| 96376 |
|
3,638 |
2,764 |
$16K |
| 94727 |
|
742 |
659 |
$16K |
| 77002 |
|
406 |
344 |
$16K |
| 72070 |
|
787 |
695 |
$16K |
| 86140 |
|
4,038 |
3,385 |
$15K |
| J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units |
422 |
128 |
$15K |
| 82330 |
|
3,038 |
2,406 |
$15K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
576 |
540 |
$15K |
| 82378 |
|
1,771 |
1,355 |
$14K |
| 85018 |
|
1,229 |
1,095 |
$14K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
681 |
621 |
$14K |
| 82746 |
|
2,868 |
2,382 |
$14K |
| 90686 |
|
3,427 |
2,978 |
$14K |
| 64635 |
|
30 |
27 |
$13K |
| 72052 |
|
330 |
299 |
$13K |
| 77336 |
|
66 |
24 |
$13K |
| 88304 |
|
490 |
425 |
$13K |
| 85379 |
|
2,929 |
2,455 |
$13K |
| 87040 |
|
3,043 |
1,710 |
$13K |
| 70498 |
|
467 |
395 |
$12K |
| 83930 |
|
1,940 |
1,631 |
$12K |
| J1630 |
Injection, haloperidol, up to 5 mg |
2,397 |
1,837 |
$12K |
| 95816 |
|
122 |
105 |
$11K |
| 85651 |
|
3,703 |
3,150 |
$11K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
164 |
139 |
$11K |
| C1769 |
Guide wire |
319 |
284 |
$11K |
| 76820 |
|
725 |
396 |
$11K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
1,739 |
1,613 |
$11K |
| 93321 |
|
178 |
155 |
$11K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
2,742 |
1,925 |
$11K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
33 |
30 |
$11K |
| 90715 |
|
3,619 |
3,185 |
$11K |
| 82570 |
|
2,662 |
2,208 |
$11K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
4,268 |
3,567 |
$10K |
| 20526 |
|
58 |
52 |
$10K |
| 84156 |
|
4,039 |
3,156 |
$10K |
| 88341 |
|
330 |
248 |
$9K |
| 94729 |
|
2,396 |
2,154 |
$9K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
15 |
12 |
$9K |
| J7999 |
Compounded drug, not otherwise classified |
722 |
541 |
$9K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,626 |
1,481 |
$9K |
| 82272 |
|
456 |
409 |
$9K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
195 |
55 |
$9K |
| 93289 |
|
392 |
344 |
$9K |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
389 |
359 |
$8K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
374 |
217 |
$8K |
| 76604 |
|
365 |
313 |
$8K |
| 72050 |
|
117 |
109 |
$8K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
3,448 |
2,737 |
$8K |
| 72114 |
|
283 |
263 |
$8K |
| 87563 |
|
1,143 |
990 |
$7K |
| J9190 |
Injection, fluorouracil, 500 mg |
923 |
309 |
$7K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,144 |
991 |
$7K |
| 76870 |
|
242 |
222 |
$7K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
2,659 |
1,956 |
$7K |
| 89051 |
|
278 |
177 |
$7K |
| 97167 |
|
141 |
116 |
$7K |
| 82803 |
|
2,730 |
2,121 |
$7K |
| 96411 |
|
711 |
455 |
$7K |
| J1940 |
Injection, furosemide, up to 20 mg |
1,588 |
867 |
$7K |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
741 |
594 |
$7K |
| 84520 |
|
1,403 |
1,115 |
$7K |
| 87147 |
|
2,794 |
2,561 |
$7K |
| 77049 |
|
28 |
26 |
$7K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
428 |
340 |
$7K |
| 82010 |
|
1,724 |
1,402 |
$7K |
| 82140 |
|
1,018 |
793 |
$7K |
| 84153 |
|
1,023 |
894 |
$6K |
| 93976 |
|
81 |
73 |
$6K |
| A4648 |
Tissue marker, implantable, any type, each |
45 |
38 |
$6K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,112 |
830 |
$6K |
| 84550 |
|
2,695 |
2,098 |
$6K |
| 93246 |
|
402 |
355 |
$6K |
| 72156 |
|
31 |
30 |
$6K |
| 12002 |
|
123 |
113 |
$6K |
| 82274 |
|
894 |
823 |
$6K |
| 91200 |
|
135 |
124 |
$6K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
1,342 |
1,130 |
$6K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
1,767 |
931 |
$6K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
48 |
40 |
$5K |
| 77066 |
Tomosynthesis, mammo |
1,521 |
1,365 |
$5K |
| 73700 |
|
144 |
133 |
$5K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,742 |
1,256 |
$5K |
| 58300 |
|
112 |
107 |
$5K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
358 |
294 |
$5K |
| 85045 |
|
1,362 |
1,012 |
$5K |
| 86705 |
|
15 |
12 |
$5K |
| J2060 |
Injection, lorazepam, 2 mg |
1,764 |
1,352 |
$5K |
| 84165 |
|
908 |
734 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
236 |
171 |
$4K |
| 82248 |
|
171 |
153 |
$4K |
| 70487 |
|
13 |
13 |
$4K |
| J9045 |
Injection, carboplatin, 50 mg |
604 |
342 |
$4K |
| 97163 |
|
76 |
69 |
$4K |
| J1953 |
Injection, levetiracetam, 10 mg |
1,066 |
657 |
$4K |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
237 |
223 |
$4K |
| J0475 |
Injection, baclofen, 10 mg |
15 |
12 |
$4K |
| 72158 |
|
29 |
25 |
$4K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
893 |
619 |
$4K |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
118 |
103 |
$4K |
| 76981 |
|
40 |
35 |
$4K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
525 |
226 |
$4K |
| 86038 |
|
829 |
698 |
$4K |
| 72128 |
|
165 |
135 |
$4K |
| 82270 |
|
542 |
454 |
$4K |
| 87522 |
Neg quan hep c or qual rna |
275 |
239 |
$4K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
1,983 |
1,666 |
$4K |
| J7297 |
Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg |
12 |
12 |
$3K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
1,375 |
1,104 |
$3K |
| 93299 |
|
133 |
123 |
$3K |
| 86300 |
|
354 |
286 |
$3K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
101 |
52 |
$3K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
1,280 |
1,096 |
$3K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
207 |
171 |
$3K |
| 76827 |
|
241 |
198 |
$3K |
| 29125 |
|
274 |
243 |
$3K |
| 78264 |
|
15 |
14 |
$3K |
| J3480 |
Injection, potassium chloride, per 2 meq |
543 |
353 |
$3K |
| 84450 |
|
1,166 |
960 |
$3K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
45 |
36 |
$3K |
| G0008 |
Administration of influenza virus vaccine |
1,171 |
953 |
$3K |
| 94664 |
|
27 |
25 |
$3K |
| 86334 |
|
445 |
340 |
$3K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
284 |
200 |
$2K |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
43 |
41 |
$2K |
| 76813 |
|
51 |
42 |
$2K |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
44 |
41 |
$2K |
| 64400 |
|
13 |
12 |
$2K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
143 |
66 |
$2K |
| 82105 |
|
234 |
195 |
$2K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
1,014 |
843 |
$2K |
| 84134 |
|
413 |
335 |
$2K |
| 73100 |
|
83 |
71 |
$2K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
160 |
146 |
$2K |
| 87106 |
|
927 |
775 |
$2K |
| 83883 |
|
250 |
202 |
$2K |
| 82340 |
|
106 |
98 |
$2K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
20 |
18 |
$2K |
| G0498 |
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion |
124 |
75 |
$2K |
| 73140 |
|
43 |
41 |
$2K |
| 74230 |
|
66 |
56 |
$2K |
| 19083 |
|
13 |
12 |
$2K |
| 69200 |
|
12 |
12 |
$2K |
| 73718 |
|
18 |
13 |
$2K |
| 95819 |
|
28 |
26 |
$2K |
| 82375 |
|
15 |
12 |
$2K |
| 92523 |
|
42 |
38 |
$2K |
| 78306 |
|
12 |
12 |
$2K |
| 70360 |
|
30 |
27 |
$2K |
| 74022 |
|
133 |
121 |
$2K |
| 82951 |
|
150 |
142 |
$2K |
| Q3014 |
Telehealth originating site facility fee |
2,510 |
1,885 |
$1K |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
24 |
12 |
$1K |
| 31500 |
|
30 |
24 |
$1K |
| 86592 |
|
380 |
344 |
$1K |
| 94760 |
|
217 |
169 |
$1K |
| 93225 |
|
27 |
24 |
$1K |
| 92611 |
|
33 |
29 |
$1K |
| 86923 |
|
349 |
285 |
$1K |
| 85660 |
|
195 |
159 |
$1K |
| 99215 |
Prolong outpt/office vis |
65 |
37 |
$1K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
908 |
771 |
$1K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
389 |
328 |
$1K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
970 |
674 |
$1K |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
31 |
28 |
$1K |
| 84145 |
|
459 |
390 |
$1K |
| 90662 |
|
572 |
476 |
$1K |
| 87581 |
|
3,097 |
2,898 |
$1K |
| 80164 |
|
85 |
71 |
$1K |
| C1889 |
Implantable/insertable device, not otherwise classified |
142 |
112 |
$996.96 |
| 76857 |
|
14 |
13 |
$994.01 |
| 86160 |
|
339 |
279 |
$863.60 |
| 87529 |
|
12 |
12 |
$817.08 |
| 84132 |
|
360 |
291 |
$755.11 |
| 92610 |
|
56 |
43 |
$742.63 |
| 70480 |
|
18 |
15 |
$728.24 |
| 93288 |
|
19 |
16 |
$720.33 |
| 64615 |
|
15 |
14 |
$703.57 |
| 51702 |
|
151 |
106 |
$695.56 |
| J2785 |
Injection, regadenoson, 0.1 mg |
590 |
494 |
$666.16 |
| 83520 |
|
297 |
246 |
$624.95 |
| 81002 |
|
46 |
43 |
$592.70 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
22 |
13 |
$573.03 |
| 86430 |
|
174 |
143 |
$565.54 |
| C9113 |
Injection, pantoprazole sodium, per vial |
1,119 |
569 |
$540.61 |
| 70490 |
|
14 |
12 |
$536.77 |
| 84460 |
|
452 |
387 |
$535.02 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
173 |
164 |
$512.11 |
| 72157 |
|
14 |
13 |
$500.94 |
| 73620 |
|
57 |
41 |
$488.62 |
| J9267 |
Injection, paclitaxel, 1 mg |
251 |
127 |
$488.11 |
| 85014 |
|
47 |
39 |
$480.02 |
| 73000 |
|
13 |
12 |
$441.78 |
| 87505 |
|
34 |
27 |
$435.96 |
| 77076 |
|
14 |
12 |
$406.22 |
| 84436 |
|
129 |
103 |
$356.84 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
64 |
53 |
$321.94 |
| 93270 |
|
12 |
12 |
$262.25 |
| 94660 |
|
16 |
12 |
$254.11 |
| 82150 |
|
448 |
383 |
$250.93 |
| 81225 |
|
96 |
84 |
$228.93 |
| 84295 |
|
153 |
124 |
$218.46 |
| 86593 |
|
85 |
67 |
$215.27 |
| 64494 |
|
77 |
72 |
$197.38 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
17 |
14 |
$195.88 |
| J0456 |
Injection, azithromycin, 500 mg |
14 |
12 |
$195.78 |
| 84480 |
|
44 |
41 |
$194.17 |
| J2780 |
Injection, ranitidine hydrochloride, 25 mg |
51 |
46 |
$188.20 |
| C9399 |
Unclassified drugs or biologicals |
34 |
26 |
$167.62 |
| 86480 |
|
17 |
14 |
$145.12 |
| 93242 |
|
13 |
13 |
$141.52 |
| 84155 |
|
31 |
26 |
$136.88 |
| 93226 |
|
13 |
12 |
$130.20 |
| 95012 |
|
16 |
12 |
$124.56 |
| 87206 |
|
80 |
36 |
$123.25 |
| J1643 |
Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units |
40 |
27 |
$112.13 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
226 |
215 |
$109.09 |
| J3489 |
Injection, zoledronic acid, 1 mg |
19 |
15 |
$96.87 |
| 83721 |
|
29 |
26 |
$86.95 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
62 |
46 |
$76.77 |
| 88312 |
|
17 |
13 |
$68.06 |
| 83010 |
|
70 |
57 |
$61.25 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
37 |
25 |
$49.18 |
| 64495 |
|
59 |
57 |
$48.52 |
| 88300 |
|
28 |
24 |
$48.52 |
| 86870 |
|
21 |
12 |
$47.82 |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
14 |
14 |
$39.40 |
| J1790 |
Injection, droperidol, up to 5 mg |
364 |
304 |
$38.57 |
| J2800 |
Injection, methocarbamol, up to 10 ml |
72 |
52 |
$36.00 |
| 82947 |
|
43 |
36 |
$24.26 |
| 82945 |
|
28 |
25 |
$24.26 |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
49 |
38 |
$21.35 |
| 82533 |
|
21 |
13 |
$20.11 |
| 92526 |
|
32 |
12 |
$16.98 |
| 87181 |
|
15 |
12 |
$14.72 |
| 84300 |
|
41 |
37 |
$13.24 |
| 85384 |
|
33 |
27 |
$11.77 |
| 82131 |
|
16 |
12 |
$11.04 |
| 84466 |
|
86 |
70 |
$5.30 |
| 82784 |
|
14 |
12 |
$4.69 |
| 83540 |
|
59 |
54 |
$1.56 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
874 |
577 |
$0.16 |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
25 |
12 |
$0.00 |
| 82805 |
|
15 |
12 |
$0.00 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
15 |
14 |
$0.00 |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
23 |
13 |
$0.00 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
72 |
38 |
$0.00 |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
20 |
12 |
$0.00 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
60 |
24 |
$0.00 |
| 87150 |
|
28 |
12 |
$0.00 |
| J2310 |
Injection, naloxone hydrochloride, per 1 mg |
21 |
13 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
13 |
12 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
64 |
63 |
$0.00 |
| V2632 |
Posterior chamber intraocular lens |
101 |
83 |
$0.00 |
| 82435 |
|
130 |
107 |
$0.00 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
479 |
133 |
$0.00 |
| 90677 |
|
17 |
17 |
$0.00 |
| G0009 |
Administration of pneumococcal vaccine |
46 |
44 |
$0.00 |
| 90656 |
|
40 |
40 |
$0.00 |
| J2150 |
Injection, mannitol, 25% in 50 ml |
25 |
12 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
14 |
13 |
$0.00 |
| 90732 |
|
13 |
13 |
$0.00 |